People with an inherited bleeding disorder have a higher risk of low iron because of blood loss from bleeding. When low iron is not treated, it can turn into iron deficiency anemia over time.

London Health Sciences Centre (LHSC) has administered the first treatment in Canada using a new, one-time gene therapy that could replace a lifetime of Factor IX transfusions — a protein that helps stop bleeding.

Be Biopharma has ended its Phase 1/2 BeCoMe-9 study of BE-101, an investigational cell therapy for hemophilia B.

U.S. FDA Approves Pfizer’s HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need

New treatment for Hemophilia B brings hope to patients

Adeno-associated virus (AAV)–mediated gene therapy has emerged as a promising treatment for hemophilia B.

An Update on HEMGENIX® (etranacogene dezaparvovec-drlb) Availability

Update on adverse event involving marstacimab rebalancing agent

Severe adverse event involving marstacimab rebalancing agent

FDA approves Qfitlia.

The Coalition for Hemophilia B Responds to Pfizer’s Discontinuation of Gene Therapy for Hemophilia B

Hemlibra is not indicated for the treatment of hemophilia B, but recent studies show that it might actually be beneficial for a few hemophilia B patients. 

Prophylaxis for mild or moderate hemophilia B is becoming more common.

A controversy over a set of clinical treatment guidelines has been raging for over a year now, but you probably haven’t heard about it.

Dr. Clark on treatments for hemophilia B patients.

Most B inhibitor patients probably did not acquire their inhibitors by ID contact, but it’s possible and needs more study. 

Hemophilia B suffers from having too few patients as subjects for research.  Because of that, some of the knowledge about hemophilia B is extrapolated from studies of hemophilia A.